Product vision |
|
Dosing |
|
Efficacy |
Efficacy in adults established when used with chloroquine Paediatric pharmacokinetic bridging study shows relapse-free efficacy rate at 4 months of 95% (95% confidence interval: 85%; 98%) in children less than 16 years of age
|
Key features |
- Single-dose treatment to prevent relapse of P. vivax malaria
- Contraindicated in glucose-6-phosphate dehydrogenase (G6PD) deficiency
|
Challenges |
|
Status |
- Marketing authorization application (MAA) variation submitted to Australian Therapeutic Goods Administration (TGA) and under review
|
Next milestone |
|
MMV Project Director |
|